Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 9:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Oral placebo tablet Clear all
Recruiting Phase 3 Interventional

A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

NCT06667700
View directory record Official record
Conditions
Coronavirus Disease (COVID-19)
Interventions
Molnupiravir, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
3,082 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
71
States / cities
Cullman, Alabama • Paradise Valley, Arizona • Phoenix, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes

NCT01456195
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Fasiglifam
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
55
States / cities
Dothan, Alabama • Muscle Shoals, Alabama • Goodyear, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2016 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Male Patients

NCT01262456
View directory record Official record
Conditions
Nocturia
Interventions
Desmopressin, Placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
51
States / cities
Anniston, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 2 Interventional

Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis

NCT00811902
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Nerispirdine, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 25, 2016 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT)

NCT04706975
View directory record Official record
Conditions
Pruritus, Notalgia Paresthetica
Interventions
difelikefalin 2.0 mg, Placebo
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
26
States / cities
Fort Smith, Arkansas • Hot Springs, Arkansas • Rogers, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated May 21, 2023 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer

NCT00645177
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
ABT-869, paclitaxel, Placebo for ABT-869
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
San Francisco, California • Harvey, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 28, 2013 · Synced Sep 28, 2026, 9:03 PM EDT
Terminated Phase 2 Interventional Results available

A Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects With Idiopathic Pulmonary Fibrosis

NCT05032066
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
HZN-825, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
22
States / cities
Birmingham, Alabama • Palm Springs, California • Clearwater, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease

NCT01732822
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Ticagrelor, Clopidogrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
50 Years to 130 Years
Enrollment
13,885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
290
States / cities
Alexander City, Alabama • Auburn, Alabama • Birmingham, Alabama + 239 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2017 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Results available

A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma

NCT00108953
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin, Doxorubicin/Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
15
States / cities
Birmingham, Alabama • Beverly Hills, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Healthy Combine Study

NCT03136705
View directory record Official record
Conditions
Healthy
Interventions
Nicotinamide, Lanthanum Carbonate, Lanthanum Carbonate Placebo, Nicotinamide Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Results available

A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches

NCT00781456
View directory record Official record
Conditions
Migraine
Interventions
91-day Levonorgestrel Oral Contraceptive, Placebo
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 34 Years · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
22
States / cities
La Mesa, California • San Diego, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2017 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

COVID-19 Study of Safety and Tolerability of Alvelestat

NCT04539795
View directory record Official record
Conditions
Covid19
Interventions
Alvelestat, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Results available

An Active-Controlled Early Phase Study of Elpipodect (MK-8189) in Adults With Schizophrenia (MK-8189-005)

NCT03055338
View directory record Official record
Conditions
Schizophrenia, Acute Episode
Interventions
Elpipodect, Risperidone, Placebo matching MK-8189, Placebo matching risperidone
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
28
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Bellflower, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults

NCT00118898
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir/Lamivudine, Atazanavir, Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate, Ritonavir, Abacavir/Lamivudine placebo, Emtricitabine/Tenofovir disoproxil fumarate placebo
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
16 Years and older
Enrollment
1,864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
51
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Liraglutide on Heart Frequency in Healthy Volunteers

NCT01516255
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, placebo, moxifloxacin, electrocardiogram (ECG)
Drug · Procedure
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users

NCT03341078
View directory record Official record
Conditions
Methamphetamine-dependence
Interventions
Ibudilast, Placebo Oral Tablet
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 55 Years
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

NCT00660387
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Levodopa carbidopa intestinal gel (LCIG), Placebo Gel, Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets, Placebo (PBO) oral capsules, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
Drug · Device
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
30 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
11
States / cities
Birmingham, Alabama • Fountain Valley, California • Oceanside, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B

NCT00095121
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Placebo (PLB), Adefovir Dipivoxil (ADV), Lamivudine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
2 Years to 17 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 3 Interventional Results available

Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress

NCT02196506
View directory record Official record
Conditions
Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
Interventions
Placebo + ADT, Brexpiprazole +ADT
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
837 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
30
States / cities
Birmingham, Alabama • Beverly Hills, California • Denver, Colorado + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Vilazodone in Major Depressive Disorder

NCT01473381
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vilazodone, Placebo to citalopram, Placebo to vilazodone, Citalopram
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
54
States / cities
Birmingham, Alabama • Dothan, Alabama • Scottsdale, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2014 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 2 Interventional

A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT04129619
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
ORP-101, Placebo
Drug
Lead sponsor
OrphoMed, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
74
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Developing Oral LT3 Therapy for Heart Failure - HFpEF

NCT04111536
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Low Triiodothyronine Syndrome
Interventions
liothyronine, Placebo
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Sep 28, 2026, 9:03 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).

NCT06412666
View directory record Official record
Conditions
Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy
Interventions
Aficamten, Placebo
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
12 Years to 17 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
24
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 28, 2026, 9:03 PM EDT
Completed Phase 2 Interventional Results available

Investigation of the Gut Microbiota in Regulating Nutrient Absorption in Humans

NCT02037295
View directory record Official record
Conditions
Obesity
Interventions
Vancomycin, Placebo oral tablet, Overfeeding diet (OF), Underfeeding diet (UF)
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Sep 28, 2026, 9:03 PM EDT